Explore the categories so you can find more about your search.

Categorie > Cardiovascular / Cardiology

Patients More Likely To Stay On Lipitor Than Simvastatin, A Large Observational Study Shows

Categorie : Cardiovascular / Cardiology
Pfizer announced that new statin users who took LipitorŪ (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims database ...

read more Pfizer announced that new statin users who took LipitorŪ (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims database read more Tue Jul 2008 Tue Jul 2008

Diet May Modify Leading Worldwide Cause Of Cardiovascular Disease

Categorie : Cardiovascular / Cardiology
A new article indicates that an increased intake in minerals such as potassium, and possibly magnesium and calcium by dietary means may reduce the risk of high blood pressure and decrease blood pressure in people with hypertension. A high intake of these minerals in the diet may also reduce the risk ...

read more A new article indicates that an increased intake in minerals such as potassium, and possibly magnesium and calcium by dietary means may reduce the risk of high blood pressure and decrease blood pressure in people with hypertension. A high intake of these minerals in the diet may also reduce the risk read more Tue Jul 2008 Tue Jul 2008

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results Of APD791 For The Treatment Of Arterial Thrombosis

Categorie : Cardiovascular / Cardiology
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatm ...

read more Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatm read more Tue Jul 2008 Tue Jul 2008

Cardiovascular Disease Prevention Efforts Could Reduce Heart Attacks By 36%, Strokes By 20% In 30 Years, Study Finds

Categorie : Cardiovascular / Cardiology
Prevention efforts that include proven methods for reducing cardiovascular disease could reduce heart attacks by 36% and strokes by 20% over the next three decades, according to a report published online Monday in the journal Circulation, the Oakland Tribune reports (Bohan, Oakland Tribune, 7/7). ...

read more Prevention efforts that include proven methods for reducing cardiovascular disease could reduce heart attacks by 36% and strokes by 20% over the next three decades, according to a report published online Monday in the journal Circulation, the Oakland Tribune reports (Bohan, Oakland Tribune, 7/7). read more Tue Jul 2008 Tue Jul 2008

Insight Into Development Of Congenital Circulatory Defects

Categorie : Cardiovascular / Cardiology
University of Pittsburgh-led researchers could provide new insight into how two common congenital circulatory problems - aortic arch deformity and arteriovenous malformations (AVMs) - develop in humans, as reported in the June 15 edition of Developmental Biology. ...

read more University of Pittsburgh-led researchers could provide new insight into how two common congenital circulatory problems - aortic arch deformity and arteriovenous malformations (AVMs) - develop in humans, as reported in the June 15 edition of Developmental Biology. read more Tue Jul 2008 Tue Jul 2008

Kidney Disease Linked To Lower Medication Use After Heart Attack

Categorie : Cardiovascular / Cardiology
Patients with kidney disease especially end-stage renal disease (ESRD) requiring dialysis are less likely to receive recommended medications after a heart attack, reports a study in the September 2008 Clinical Journal of the American Society of Nephrology (CJASN). ...

read more Patients with kidney disease especially end-stage renal disease (ESRD) requiring dialysis are less likely to receive recommended medications after a heart attack, reports a study in the September 2008 Clinical Journal of the American Society of Nephrology (CJASN). read more Tue Jul 2008 Tue Jul 2008

Novel Approach May Protect Against Heart Attack Injury

Categorie : Cardiovascular / Cardiology
Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since alr ...

read more Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since alr read more Tue Jul 2008 Tue Jul 2008

Mayo Clinic Spearheads Research To Discover Unsuspected Gene For Atrial Fibrillation

Categorie : Cardiovascular / Cardiology
Mayo Clinic researchers have found a gene mutation linked to one family's hereditary form of atrial fibrillation. Researchers hope this discovery will lead to better understanding of the disease and, eventually, better ways to predict, prevent and treat the heart rhythm problem. The study was bas ...

read more Mayo Clinic researchers have found a gene mutation linked to one family's hereditary form of atrial fibrillation. Researchers hope this discovery will lead to better understanding of the disease and, eventually, better ways to predict, prevent and treat the heart rhythm problem. The study was bas read more Tue Jul 2008 Tue Jul 2008

Nile Therapeutics Announces Dosing In Phase IIa Study Of CD NP In Heart Failure Patients

Categorie : Cardiovascular / Cardiology
Nile Therapeutics, Inc. (Nasdaq: NLTX), announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development fo ...

read more Nile Therapeutics, Inc. (Nasdaq: NLTX), announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development fo read more Tue Jul 2008 Tue Jul 2008

UM Cardiologist And Researcher Lead Study Identifying Predictors Of Prognosis For Heart Failure Patients

Categorie : Cardiovascular / Cardiology
In a discovery that could lead to more successful and personalized treatment, a post-doctoral fellow and the leader of the University of Miami Miller School of Medicine's Cardiovascular Division have published a study that gives physicians a critical tool in predicting the long-term course for heart ...

read more In a discovery that could lead to more successful and personalized treatment, a post-doctoral fellow and the leader of the University of Miami Miller School of Medicine's Cardiovascular Division have published a study that gives physicians a critical tool in predicting the long-term course for heart read more Tue Jul 2008 Tue Jul 2008

VIA Pharmaceuticals Completes Patient Visits In Phase 2 Carotid Endarterectomy (CEA) Trial

Categorie : Cardiovascular / Cardiology
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised carotid plaque tissue will be a ...

read more VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised carotid plaque tissue will be a read more Tue Jul 2008 Tue Jul 2008

URMC, FDA To Collaborate On National Data Repository For Heart Research

Categorie : Cardiovascular / Cardiology
The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand ma ...

read more The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand ma read more Tue Jul 2008 Tue Jul 2008

Better Outcomes In Heart Attack Patients Linked To Chest Pain Center Accreditation

Categorie : Cardiovascular / Cardiology
Hospitals accredited by the Society of Chest Pain Centers (SCPC) have been shown to perform better in the heart attack core measures established by Centers for Medicare and Medicaid Services (CMS) as compared to non-accredited hospitals, according to a national study led by an Emory University resea ...

read more Hospitals accredited by the Society of Chest Pain Centers (SCPC) have been shown to perform better in the heart attack core measures established by Centers for Medicare and Medicaid Services (CMS) as compared to non-accredited hospitals, according to a national study led by an Emory University resea read more Tue Jul 2008 Tue Jul 2008

Largest International Cardiac Surgery Study Will Compare Open-Heart Surgery With Or Without Heart-Lung Machine

Categorie : Cardiovascular / Cardiology
The world's largest cardiac surgery clinical trial, expected to involve 4,700 patients, will be undertaken by researchers at the Population Health Research Institute of Hamilton Health Sciences and McMaster University. The trial will investigate the differences in outcomes of using on-pump versu ...

read more The world's largest cardiac surgery clinical trial, expected to involve 4,700 patients, will be undertaken by researchers at the Population Health Research Institute of Hamilton Health Sciences and McMaster University. The trial will investigate the differences in outcomes of using on-pump versu read more Tue Jul 2008 Tue Jul 2008

NewCardio Announces Results Of Its Large Clinical Validation Study

Categorie : Cardiovascular / Cardiology
NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services company, revealed the results of its second external validation study of QTinno? (the "NCE2 Study"), its third and largest clinical validation study to date. The study was led by an independent industry leading cardiac safety expert w ...

read more NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services company, revealed the results of its second external validation study of QTinno? (the read more Tue Jul 2008 Tue Jul 2008

AngioScore Launches New Longer And Larger AngioSculpt(R) Devices For Treatment Of Peripheral Artery Disease

Categorie : Cardiovascular / Cardiology
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced the launch of new longer and larger AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD). The new devices have received U.S. ...

read more AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced the launch of new longer and larger AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD). The new devices have received U.S. read more Tue Jul 2008 Tue Jul 2008

CardioTech Receives FDA Approval For Export Of Second Graft Size For CardioPass Clinical Trial

Categorie : Cardiovascular / Cardiology
CardioTech International, Inc. (AMEX: CTE), a leading developer and manufacturer of advanced biomaterials for a broad range of medical devices, announced that it has received the necessary U.S. Food and Drug Administration ("FDA") approval to export its 4mm graft in further support of the ongoing Eu ...

read more CardioTech International, Inc. (AMEX: CTE), a leading developer and manufacturer of advanced biomaterials for a broad range of medical devices, announced that it has received the necessary U.S. Food and Drug Administration ( read more Tue Jul 2008 Tue Jul 2008

Automatically Sounding Out Heart Problems

Categorie : Cardiovascular / Cardiology
Sounding the chest with a cold stethoscope is probably one of the most commonly used diagnostics in the medical room after peering down the back of the throat while the patient says, "Aaaah". But, research published in the inaugural issue of the International Journal of Medical Engineering and Infor ...

read more Sounding the chest with a cold stethoscope is probably one of the most commonly used diagnostics in the medical room after peering down the back of the throat while the patient says, read more Tue Jul 2008 Tue Jul 2008

Major U.S. Health Groups Cite Aspirin Use Among Other Life-Saving Interventions

Categorie : Cardiovascular / Cardiology
Greater, appropriate utilization of aspirin and other preventive measures, such as quitting smoking, losing weight and lowering cholesterol, would reduce heart attacks by 36 percent over the next three decades, according to a report issued by three major U.S. health organizations. ...

read more Greater, appropriate utilization of aspirin and other preventive measures, such as quitting smoking, losing weight and lowering cholesterol, would reduce heart attacks by 36 percent over the next three decades, according to a report issued by three major U.S. health organizations. read more Tue Jul 2008 Tue Jul 2008

Abbott Begins Post-Approval Study Of XIENCE V? Drug Eluting Stent

Categorie : Cardiovascular / Cardiology
Abbott announced the start of the XIENCE V? USA post-approval study, with six hospital centers already recruiting and enrolling patients just one week after the U.S. Food and Drug Administration approved the XIENCE V? Everolimus Eluting Coronary Stent System. The XIENCE V USA study will evaluate the ...

read more Abbott announced the start of the XIENCE V? USA post-approval study, with six hospital centers already recruiting and enrolling patients just one week after the U.S. Food and Drug Administration approved the XIENCE V? Everolimus Eluting Coronary Stent System. The XIENCE V USA study will evaluate the read more Tue Jul 2008 Tue Jul 2008

1 | 2 | 3 | 4 next >>>



     


Custom Search